DCLAK-11

N/A

Report date: 2022/02/23 20:00:33

NME

Base Information

Drug NameDCLAK-11

Drug Alias NameDCLAK-11

ClassificationOther

Mechanisms of ActionVascular endothelial growth factor receptor 2 inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonistsEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Vascular endothelial growth factor receptor 2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A